(HealthDay News) — The Women’s Health Initiative estrogen plus progestin (WHI E+P) trial resulted in considerable economic savings, according to a study published in the May 6 issue of the Annals of Internal Medicine.

Joshua A. Roth, PhD, from the Fred Hutchinson Cancer Research Center and Group Health Research Institute in Seattle, and colleagues examined the economic return from the WHI E+P trial. Health outcomes were simulated in a decision model study for a “WHI scenario” with observed combined hormone therapy (cHT) use and a “no-WHI scenario” with cHT use extrapolated from the period before the trial.

The researchers found that there were 4.3 million fewer cHT users; 126,000 fewer breast cancer cases; 76,000 fewer cardiovascular disease cases; 263,000 more fractures; 145,000 more quality-adjusted life-years; and savings of $35.2 billion in the WHI scenario. At a willingness-to-pay level of $100,000 per quality-adjusted life-year, the net economic return of the trial was $37.1 billion ($140 per dollar invested in the trial).

“The WHI E+P trial made high-value use of public funds with a substantial return on investment,” the authors write. “These results can contribute to discussions about the role of public funding for large, prospective trials with high potential for public health effects.”

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)